Bayer HealthCare and the University of Texas' MD Anderson Cancer Center have announced that they'll be teaming up to better reach patients with the newest oncology trials. According to to the Fort Bend News, MD Anderson is one of the highest regarded cancer treatment centers in the nation. This along with the focus that the focus of Bayer HealthCare's latest initiatives include medications for tumors and rarer forms of kidney, thyroid and liver cancer make this Pharma/Academic partnership a great way to bring the latest innovation in cancer treatments to those who need the treatment the most. This partnerships also spans the globe - as the new, innovative treatments discovered in Bayer's research facilitates Berlin, Germany and Whippany, New Jersey.
The Duke Cancer Institute and Bristol-Myers Squibb also partnered to further their efforts in drug development. Representatives from the partnerships will be joining us at Partnerships in Clinical Trials for the presentation BMS’ Innovative Model of Strategic Sponsor-Site Partnerships on Tuesday, April 1. For more information on this session and the rest of the program, download the agenda. If you'd like to join us March 30-April 2, 2014, as a reader of this blog when you register to join us and mention code XP1900BLOG, you'll save $100 off the current rate.
What are some of the academic/Pharma partnerships that stand out and why?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.